448 related articles for article (PubMed ID: 17460299)
1. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
[TBL] [Abstract][Full Text] [Related]
2. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
Lei H; Velez G; Hovland P; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):42-8. PubMed ID: 18172073
[TBL] [Abstract][Full Text] [Related]
3. Growth factors outside the PDGF family drive experimental PVR.
Lei H; Velez G; Hovland P; Hirose T; Gilbertson D; Kazlauskas A
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3394-403. PubMed ID: 19324843
[TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of platelet-derived growth factor receptor β promotes vitreous-induced contraction of retinal pigment epithelial cells.
Duan Y; Wu W; Cui J; Matsubara JA; Kazlauskas A; Ma G; Li X; Lei H
BMC Ophthalmol; 2023 Aug; 23(1):344. PubMed ID: 37537538
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.
Andrews A; Balciunaite E; Leong FL; Tallquist M; Soriano P; Refojo M; Kazlauskas A
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2683-9. PubMed ID: 10509666
[TBL] [Abstract][Full Text] [Related]
6. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor.
Ikuno Y; Kazlauskas A
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2406-11. PubMed ID: 12091444
[TBL] [Abstract][Full Text] [Related]
7. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor.
Ikuno Y; Leong FL; Kazlauskas A
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3107-16. PubMed ID: 10967071
[TBL] [Abstract][Full Text] [Related]
9. PDGF receptors are activated in human epiretinal membranes.
Cui J; Lei H; Samad A; Basavanthappa S; Maberley D; Matsubara J; Kazlauskas A
Exp Eye Res; 2009 Mar; 88(3):438-44. PubMed ID: 19032953
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.
Robbins SG; Mixon RN; Wilson DJ; Hart CE; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3649-63. PubMed ID: 8088954
[TBL] [Abstract][Full Text] [Related]
11. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.
Lei H; Rhéaume MA; Velez G; Mukai S; Kazlauskas A
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):5016-21. PubMed ID: 21642621
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.
Lei H; Rheaume MA; Kazlauskas A
Exp Eye Res; 2010 Mar; 90(3):376-81. PubMed ID: 19931527
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
14. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders.
Cassidy L; Barry P; Shaw C; Duffy J; Kennedy S
Br J Ophthalmol; 1998 Feb; 82(2):181-5. PubMed ID: 9613386
[TBL] [Abstract][Full Text] [Related]
15. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
Pennock S; Haddock LJ; Eliott D; Mukai S; Kazlauskas A
Prog Retin Eye Res; 2014 May; 40():16-34. PubMed ID: 24412519
[TBL] [Abstract][Full Text] [Related]
16. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.
Praidou A; Klangas I; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S
Curr Eye Res; 2009 Feb; 34(2):152-61. PubMed ID: 19219687
[TBL] [Abstract][Full Text] [Related]
17. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor.
Ikuno Y; Kazlauskas A
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):41-6. PubMed ID: 11773010
[TBL] [Abstract][Full Text] [Related]
18. Expression of PDGF and their receptors in human retinal pigment epithelial cells and fibroblasts: regulation by TGF-beta.
Nagineni CN; Kutty V; Detrick B; Hooks JJ
J Cell Physiol; 2005 Apr; 203(1):35-43. PubMed ID: 15368539
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy.
Zheng Y; Ikuno Y; Ohj M; Kusaka S; Jiang R; Cekiç O; Sawa M; Tano Y
Jpn J Ophthalmol; 2003; 47(2):158-65. PubMed ID: 12738549
[TBL] [Abstract][Full Text] [Related]
20. [The effect of platelet-derived growth factor on the formation of proliferative vitreoretinopathy].
Liang Y; Li X; Fan J; Zhao M; Jiang Y
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):144-7. PubMed ID: 11955317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
